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a b s t r a c t
Stem cell growth and differentiation is controlled by intrinsic and extrinsic factors. The latter includes
growth factors, which are conventionally supplied in vitro in media exchanged daily. Here, we illustrate
the use of afﬁnity targeted biodegradable nanoparticles to mediate paracrine stimulation as an alter-
native approach to sustain the growth and pluripotency of mouse embryonic stem cells. Leukaemia
Inhibitory Factor (LIF) was encapsulated in biodegradable nanoparticles and targeted to the cell surface
using an antibody to the oligosaccharide antigen SSEA-1. Sustained release of LIF from nanoparticles
composed of a solid Poly(lactide-co-glycolic acid) polyester or a hydrogel-based liposomal system, we
term Nanolipogel, replenished once after each cell passage, proved as effective as daily replenishment
with soluble LIF for maintenance of pluripotency after 5 passages using 104-fold less LIF. Our study
constitutes an alternative paradigm for stem cell culture, providing dynamic microenvironmental control
of extrinsic bioactive factors beneﬁting stem cell manufacturing.
 2012 Elsevier Ltd. All rights reserved.
1. Introduction
In vitro systems supporting stem cell renewal and differentiation
are challenged by uncontrolled cell behaviour and death affecting
their efﬁciency. This undermines their utility in research, and in
translational applications such as the manufacture of speciﬁc cell
populations for screening or therapeutic purposes. Irrespective of
their scale or nature, cell culture systems conventionally supply
exogenous bioactive factors by solubilisation in culture medium.
This becomes costly during prolonged culture over weeks and
months, especially when there is a requirement for complex
cocktails of protein factors to expand or direct differentiation of
cells to a speciﬁc endpoint [1,2], as for example during directed
differentiation of human embryonic stem cells (hESC) populations
to neuronal subtypes or even expansion of mesenchymal [3] or
organ speciﬁc stem cell populations for autologous or allogeneic
transplantation [4e6]. Exogenously-supplied factors can also
support the viability or growth of undesired cell populations non-
speciﬁcally which can then compete with the production of the
required cell types or inﬂuence their function.
A relatively unexplored strategy to improve the efﬁciency of
stem cell culture is to afﬁnity target critical bioactive factors
sequestered in biodegradablemicro or nanoparticles to cell types of
interest, thereby achieving a spatially and temporally controlled
local “paracrine” stimulation of cells. Non-targeted biodegradable
nano- and microspheres containing TGF-b1, TNF-a, and retinoic
acid have been embedded with mouse embryonic stem cells
(mESCs) grown in suspension as embryoid bodies to drive differ-
entiation in vitro [7]. They have also been used to facilitate non-viral
gene transfer to hESCs [8]. In vivo, paracrine signalling is pivitol to
controlling cellular behaviour in a stem cell niche [9]. Niches are
also likely to exist in vitro, such as has been proposed to occur in the
context of bFGF signalling between differentiating and pluripotent
hESCs mediating self-renewal [10,11]. Controlled release of bioac-
tive factors can be achieved in vivo and in vitro using a spectrum of
inorganic, or organic liposome- or polymer-based systems [12,13].
We have previously demonstrated targeted delivery of biodegrad-
able encapsulates by functionalising nanoparticle surfaces with
biotin:streptavidin-anchored epitope-speciﬁc antibodies and
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shown the prospective utility of this approach for T-cell stimula-
tion, drug delivery, vaccination and immunotherapy [14e20],
including targeted delivery of the Leukocyte Inhibitory Factor (LIF)
for modulation of immune responses [17,21].
In the present study we evaluated the efﬁcacy of afﬁnity tar-
geted biodegradable nanoparticles-mediated delivery of LIF, the
essential factor for mESC self-renewal maintenance and pluri-
potency [22], as an alternative to its conventional daily replenish-
ment in culture medium. Using two different biodegradable
nanosystems that release LIF in a slow-sustained fashionean
established solid Poly(lactide-co-glycolic acid) (PLGA) polyester
[17,21] and a recently described hydrogel-based liposomal system
we termNanolipogel (NLG) - [23,24] we demonstrate the feasibility
of this approach for long-term support of embryonic stem cell
renewal, an achievement which has signiﬁcant implications for
improving the efﬁcacy of stem cell culture systems for research and
industrial and clinical applications.
2. Materials and methods
2.1. mESC culture
HM1 mESC from the 129 mouse strain were cultured on plastic tissue culture
well plates (Corning Inc.) coated with 0.1% gelatin (Sigma) in GMEM (Sigma) sup-
plemented with 5% foetal calf serum (Sigma), 1% L-Glutamine (Invitrogen), 1% Non-
Essential Amino Acids (Invitrogen), 1% Sodium Pyruvate (Invitrogen), 0.1 mM 2-
mercaptoethanol (Sigma) at 37C, 5% CO2. For standard treatment medium was
supplemented with soluble LIF (25 ng/ml; Millipore). Cells were passaged using
0.025% trypsin/EDTA for 3 min at 37C.
2.2. Preparation of LIF-PLGA
Murine LIF was encapsulated in avidin-coated PLGA nanoparticles using
a modiﬁed version of a previously described water/oil/water double emulsion
technique [25]. Brieﬂy, 50 mg LIF was dissolved in 200 ml PBS and added dropwise
with vortexing to 100 mg PLGA in 2 ml dichloromethane. The resulting emulsion
was added to 4 ml of aqueous surfactant solution containing 2.5 mg/ml PVA and
2.5 mg/ml avidin-palmitate bioconjugate [25], and sonicated to create an emulsion
containing nano-sized droplets of polymer/solvent, LIF and surfactant. Solvent was
removed by magnetic stirring at room temperature; hardened nanoparticles were
then washed 3 in distilled water and lyophilized for long-term storage.
2.3. Preparation of NLG-LIF
The preparation of this system has been previously described [24]. Lyophilized
liposomes were reconstituted with a solution containing 5% (w/v) polymer PEG-
PLA-acrylate, 2.5 mg/mL Ciba Irgacure 2959 and 10 mg/ml LIF. The liposomes were
then irradiated under UV light for 8 min with a Blak-Ray long wave ultraviolet lamp
(Model B 100) at a 10 cm working distance. The resulting NLG were pelleted by
centrifugation (5 min at 7200 rcf) and resuspended in PBS. Loaded lipogels were
then conjugated by NHS/EDC chemistry with avidin; the centrifugation/resus-
pension procedure was repeated three times.
2.4. Afﬁnity targeting nanoparticles
SSEA-1 targeted nanoparticles were formed by reacting avidin-coated nano-
particles in GMEMwith 4 ml of biotin-anti-SSEA-1 (0.5 mg/mL; BioLegend) per mg of
nanoparticles for 15 min and used immediately.
2.5. Nanoparticle characterisation
Nanoparticle size and morphology were analysed via scanning electron
microscopy (SEM) and a Nanosight LM-10 imaging station. Release of LIF was
measured by incubating nanoparticles in PBS at 37C and measuring LIF concen-
trations in supernatant fractions by ELISA. Total encapsulation was approximated as
the amount of LIF released over a seven-day period and percent encapsulation
efﬁciency calculated as total encapsulation divided by maximum theoretical
encapsulation.
2.6. Afﬁnity targeted delivery to mESCs on mitotically inactivated feeder cells
mESCs (2.5  104 cells/cm2) were plated onto wells of 4 chamber slides with
MEFs in 500 ml of medium. After 24 h medium was replaced and cells were treated
overnight with medium supplemented with 10 mg/ml SSEA-1 targeted (or untar-
geted, i.e. antibody-free) rhodo/biotin-avidin-adaptor NLG or PLGA. MEFs were
employed as negative control to evaluate whether the functionalised membrane
provides a non-speciﬁc afﬁnity targeting system. Rhodamine incorporation was
assessed by live cell immunoﬂuorescence.
2.7. Optimisation of afﬁnity targeted delivery of LIF for mESC renewal in feeder-free
culture
mESCs (2.5  104 cells/cm2) were plated in gelatin-coated wells of 4 chamber
slides. After 24 h cells were incubated overnight with SSEA-1 targeted LIF-loaded
nanoparticles at nominal concentrations (1, 10, 100, 1000 mg/ml). In parallel,
different concentrations of soluble LIF (5, 10, 25, 50 ng/ml) were used. 25 ng/ml of
soluble LIF was set as positive control. No soluble LIF and empty nanoparticles
(1000 mg/ml) were employed as negative controls. At the end of the incubation,
nanoparticle-treated cells were washed twice in PBS and medium with no soluble
LIF was replaced everyday for the following 5 days. Soluble LIF-supplemented
medium was also replaced everyday over the experiment period. The effect of
each treatment on cell pluripotent speciﬁcmarkers and proliferationwere evaluated
by immunocytochemistry for Oct-4 and WST-1 test (Calbiochem Rapid Cell
Proliferation Kit, Merck Biosciences).
2.8. Clonogenicity assessment
mESCs were plated at low density (500 cells/10 cm2) onto gelatin-coated Petri
dish. After 24 h cells were incubated overnight with SSEA-1 targeted LIF-loaded NLG
or PLGA at the optimised concentration (10 mg/ml) prior or after trypsinisation. In
parallel, cells were grown in absence or in presence of soluble LIF (25 ng/ml) to be
used as negative and positive control. At the end of the incubation, nanoparticle
treated cells were washed twice in PBS and medium with no soluble LIF was
replaced everyday for 5 days. Soluble LIF-supplemented medium was also replaced
everyday over the experiment period. Cells were ﬁxed and stained by using the
Alkaline Phosphatase detection kit (Millipore) and following the manifacturer’s
instructions.
2.9. Exempliﬁcation of long-term renewal in feeder-free culture
The optimal treatment with LIF-loaded PLGA and NLG was applied over a 5
weeks period once per week, following trypsin/EDTA dissociation and replating. No
LIF and soluble LIF (25 ng/ml) were used as negative and positive control, respec-
tively. Every 7 days cells were replated at 2.5  104 cells/cm2. At the end of the
treatment, cells were assessed for pluripotency markers, karyology and differenti-
ation potential.
2.10. Growth rate analysis
mESCs were seeded, treated with the optimised concentration of targeted
nanoparticles (10 mg/ml for both PLGA and NLG) and counted everyday for 7 days
using a haemocytometer. Positive and negative controls cell growth was also eval-
uated. Cell number versus timewere plotted in order to calculate the speciﬁc growth
rates during the exponential growth phase for each treatment. Triplicate counts
were gathered at each passage.
2.11. Electric cell-substrate impedance sensing (ECIS) assay
Impedance characterisation of mESC behaviour was assessed with the ECIS
system (ECIS Zq, Applied Biophysics). Cells were grown on eight-well ECIS arrays
(8W10þ; Applied Biophysics) containing 40 250-mm gold microelectrodes per well.
Two ECIS arrays were recorded in parallel, for a total of 16 wells per experiment.
Measurements were performed directly in cell culture medium, allowing real-time
monitoring. Both the ECIS arrays and the measurement station were kept in an
incubator with high humidity at 37C and 5% CO2. Prior to cell seeding, electrode
arrays were coated with 0.1% gelatin. Cells were plated in suspension at a density of
5  104 cells/cm2 in each well. After treatment (10 mg/ml nanoparticles), the resis-
tance of the celleelectrode interface for each of the 16 wells was measured everyday
for 30 min. During the measurement, a non-invasive electric ﬁeld of 1 mA was
applied. Cells grown in absence of LIF (n ¼ 3) and in presence of soluble LIF (n ¼ 3)
were used as negative and positive control, respectively, and compared to cell
treated with PLGA (n ¼ 3), NLG (n ¼ 3) and empty nanoparticles (n ¼ 3). Impedance
of a cell-free electrode in media (n ¼ 1) was also measured as a background signal.
2.12. Immunoblotting
mESCs were plated on gelatin-covered 6-well plates (106 cells/well). The next
day, the cells werewashedwith PBS and culturedwith GMEMmedium free of serum
and LIF containing 1% L-Glutamine, 1% Non-Essential Amino Acids, 1% Sodium
Pyruvate, 0.1 mM 2-mercaptoethanol. Four hours later, the cells were stimulated
with soluble murine LIF (25 ng/ml), LIF-loaded nanoparticles (PLGA or NLG) or
empty nanoparticles for 10 min and 24 h. After the induction, the cells were har-
vested with lysis buffer (10% Glycerol (Sigma), 3% SDS (Sigma), 62.5 mM TrisHCl
(Sigma) pH 6.8, 0.005% Bromophenol blue (Sigma), 3% b-mercaptoethanol) and
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proteins were resolved on a 10% SDS-polyacrylamide gel and trasferred to a nitro-
cellulose membrane (BioRad Laboratories). The blot was blocked with TBS-T (20 mM
TriseHCl, pH 7.6, 136 mM NaCl (Sigma), and 0.1% Tween-20 (Sigma)) containing 5%
skimmed milk or 3% BSA and then incubated with the primary antibody for 1 h at
room temperature. After washing with TBS-T, the membrane was incubated with
horseradish peroxidase-conjugated secondary antibody for 1/2 h at room temper-
ature. Signals were detected with Pierce ECL Western Blotting Substrate (Pierce,
Thermo Fisher Scientiﬁc). The antibodies used were phospho STAT-3 (Tyrosine 705;
1:1000; Cell Signalling), STAT-3 (1:1000; Cell Signalling) and Oct-4 (1:1000; Santa
Cruz Biotechnology Inc.). Secondary antibodies were rabbit IgG and mouse IgG1
(1:5000; Amersham Biosciences). To quantify the level of activation of the protein in
relation to the total protein loaded the software ImageJ was used on the developed
X-ray ﬁlms of the blots.
2.13. Immunostaining
Brieﬂy, mESCs on were washed once with PBS and ﬁxed with 4% PFA. After
permeabilisation in 0.2% Igepal (Sigma) and blocking in 10% normal rabbit serum
(Millipore), cells were incubated with primary antibodies Oct-4 (1:50; Santa Cruz
Biotechnology) and Nanog (1:30; R&D systems) overnight at 4 C. Visualisationwith
secondary antibodies was performed using Alexaﬂuor antibodies 488 and 555
(Invitrogen), and nuclei were counterstained with 40 ,6-diamidino-2-phenylindole,
dilactate (DAPI). To stain live cells mESCs were washed once with GMEM medium
supplemented with 0.1% BSA. Cells were then incubated with the directly conju-
gated antibody (SSEA-1 Alexaﬂuor-488; 1:30, BioLegend) for 30 min at room
temperature in the dark. Nuclei were counterstained with Hoechst. Imaging analysis
was carried out using a Leica SPE microscope.
2.14. Flow cytometry analysis
Single cell preparationwas obtained by incubationwith 0.025% trypsin/EDTA for
5e10min at 37C, resuspended in FACS PBS (0.1% BSA, 0.1% sodium Azide in PBS) and
incubated with directly conjugated antibody (SSEA-1 Alexaﬂuor-488) for 20 min.
Flow cytometry data were acquired using a Becton Dickinson FACSCalibur cytom-
eter. The percentage of positive cells was established using FlowJo software by
comparing experimental cells to control groups (no LIF- and standard condition-
treated cells) at each passage.
2.15. RT-PCR
mESC RNA was prepared from snapefrozen cell pellets using Trizol reagent
(Invitrogen) and then samples were treated with RQ1 RNase-Free DNase (Promega).
RNA concentration and purity were measured using NanoDrop Spectrophotometer
(NanoDrop ND1000). Complementary DNA was synthesized from 500 ng of total
RNA using Superscript III reverse-transcription kit (Invitrogen) with oligo-dT
primers. Mouse Oct-4, Nanog, PEM and Sox-2 expression was determined using in
25 ﬁnal volume using Taq DNA polymerase (Bioline Reagents Ltd.). b-actin was
employed as reference gene. Primers used and their characteristics are listed in
Table 1.
2.16. Undirected embryoid body (EB) mediated differentiation
Differentiation potential was assessed by undirected in vitro assay. mESCs (1000
cells per microwell) were aggregated in AggreWell plates (StemCell Technology Inc.)
by centrifugation in serum-free conditions. One day later EBs were transferred into
six-well Ultra-low Adherent plates (Stem Cell Technology) and grown in suspension
for 7 days at 37 C in 5% CO2 in standard mES medium without LIF. Cells were then
plated into 4well-culture slides (Becton Dickinson Labware) then grown at 37C in
5% CO2 in the same medium for one week.
2.17. Teratoma induction
mESCs treated with PLGA and NLG for 5 passages were suspended at 5  106
cells per 100 ml in standard HEPES-buffered DMEM. Approximately 20 ml of this cell
slurry was transferred under the kidney capsule of 129/Ola strain mice using a ﬁne
glass capillary. One month after injection, teratomas were dissected, ﬁxed overnight
in 10% phosphate-buffered formalin and embedded in parafﬁn. Sections were
stained with Masson’s Tricolour stain. Mice were housed in speciﬁc pathogen-free
conditions and the care of the animals was in accordance with UK Home Ofﬁce
regulations.
2.18. Karyology
Cells, were plated 3 days prior to performing chromosome spreads and pro-
cessed with the Karyomax kit (Invitrogen). Five different metaphase spreads were
examined per treatment.
2.19. Statistical analysis
All statistical analyses were performed using the Statistics Package for the Social
Sciences, version 11.0 (SPSS Inc., Chicago, IL, USA). The KolmogoroveSmirnov test
was used to determine whether the data were random samples from a normal
distribution. For normally distributed variables, an unpaired t-test was applied.
Replicates (n ¼ 3 for each experiment, n ¼ 5 for clonogenicity) were performed and
the results represent mean  SD. For ECIS measurements ANOVA followed by
Tukey’s multicomparison analysis was performed. A level of P  0.05 was accepted
as statistically signiﬁcant and P 0.01 as highly statistically signiﬁcant. All data from
ELISA are presented as the mean  SD from triplicate samples at the speciﬁed time
points.
3. Results
3.1. Characterisation of nanoparticle kinetics and targeting
PLGA and NLG nanoparticles containing LIF were functionalised
for afﬁnity targeted delivery of LIF to mESC by streptavidin-biotin
cross-linkage of an antibody to SSEA-1 to particle surfaces
(Fig. 1a, b). Nanoparticle preparations consisted of approximately
107 nanoparticles per mg of encapsulating matrix with an average
diameter of 200  50 nm. For both formulations the concentration
of LIF was approximately 1 ng/mg equating to 107 ng or 2400
molecules of LIF per nanoparticle (LIF molecular weight ¼ 25 kD).
To insure that cells received the same dose of LIF regardless of
formulation, the NLG polymer to lipid ratio was adjusted to yield
similar kinetics as PLGA consisting of constant release over 4 days
(shown for PLGA, Fig. 1 d) [17,24].
To assess the capacity of anti-SSEA-1 surface functionalised
nanoparticles to achieve an afﬁnity targeted delivery of an encap-
sulant to mESCs, we ﬁrst delivered a pH sensitive dye that only
ﬂuoresces upon internalization (pH Rhodo, Invitrogen). mESCs
grown on mouse embryonic ﬁbroblasts (MEF), or MEF alone were
exposed to nanoparticles at different concentrations (1, 10, 100 mg/
ml) for 30 min, 1 h, 3 h and overnight. As a negative control cells
were treatedwith untargeted nanoparticles (ie. no SSEA-1 antibody
on their surface) for the same length of time. After 3 h or more of
exposure to targeted and untargeted nanoparticles of both formu-
lations at 100 mg/ml, non-speciﬁc rhodamine signal in SSEA-1-
negative MEFs was observed. However, shorter exposures (1 h)
at lower concentrations (ie. 1 mg/ml) diminished rhodamine stain-
ing in SSEA-1 positive mESCs. These experiments suggested that
afﬁnity targeted stimulation of mixed cell populations requires
optimisation. In this instance, the optimum conditions for afﬁnity
targeting of SSEA-1 positive mESCs on MEF for both nanoparticle
formulations was overnight treatment at 10 mg/ml (Fig. 2a).
3.2. Short-term paracrine stimulation for mESC renewal in feeder-
free culture
Our next objective was to demonstrate whether nanoparticles-
mediated delivery of LIF could be beneﬁcial in the short-term
Table 1
Oligonucleotide sequences used for RT-PCR analysis.
Markers Accession
number
Prod.
Size
(bp)
Sequences (50 / 30) Annealing
temperature
Oct-4 NM_013633 521 S:AAGGTGGAACCAACTCCCGA
A:GTAGCCTCATACTCTTCTCG
62 C
Nanog NM_028016 620 S:AGCACCAGTGGAGTATCCCAG
A:TCTTCCGAAGGTCAGGAGCTC
55 C
PEM NM_008818 514 S:TCCAGCCGCAAGGTCACCAGG
A:TCCTCCTGGTTCTTCTGGCC
58 C
Sox-2 NM_011443 362 S:CCGCGTCAAGAGGCCCATG
A:AGCTGTCCATGCGCTGGTTC
56 C
b-actin NM_007393.3 242 S:CGTGGGCCGCCCTAGGCACCA
A:TTGGCCTTAGGGTTCAGGGGGG
62 C
Bp: base pairs; S: sense; A: antisense.
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context of mESC clonal outgrowth. mESCs were plated on gelatin-
coated at low density following Trypsin/EDTA-mediated dissocia-
tion to single cells. Cells were treated with 10 mg/ml of SSEA-1
targeted nanoparticles overnight either pre- or post-passaging
and then cultured for an additional 5 days with daily exchange of
basal medium with no additional LIF added. Giemsa and Alkaline
Phosphatase (ALP) staining was used to assess total cell colony
frequency and the proportion which remained undifferentiated,
respectively. Compared to the positive control wherein LIF was
solublised conventionally, total colony frequency was signiﬁcantly
reduced in the negative control (no LIF) and all treatment groups
(P < 0.01) with the exception of post-passage treatment with NLG-
LIF. LIF delivered using the NLG formulation of nanoparticles also
yielded as high a proportion of ALPþ colonies as the positive
control, irrespective of whether cells were treated before or after
passaging (Fig. 2 b). By contrast, pre- and post-passaging treatment
with PLGA-LIF was comparable to LIF-negative control suggesting
that in the context of low density outgrowth it was inferior to NLG.
We next considered nanoparticles-mediated delivery of LIF for
purposes of mESC self-renewal under routine feeder-free conditions
for cell expansion. For this, we adopted a protocol of treating cells
with nanoparticles overnight (w16 h) the ﬁrst day after plating at
a density of 2.5104 cells/cm2 followedbydailyexchange of only the
basal medium as for the preceding experiment (Fig. 2c). Treatments
withSSEA-1 targetedNLG-LIFandPLGA-LIFnanoparticlesat10mg/ml
were compared with soluble LIF at 25 ng/ml, SSEA-1 targeted empty
(LIF-free) nanoparticles at 1000 mg/ml and no LIF. After 5 days
cultureswere evaluated by immunostaining for pluripotencymarker
(Oct-4) and bioreduction of the stable tetrazolium salt, WST-1, the
latter an indication of the number of metabolically active cells in
culture (Fig. 3 a,b). In the absence of LIF (ie. no LIF supplementation of
mediumor treatmentwith of LIF-free SSEA-1 targetednanoparticles,
“Empty NP”), there was an anticipated qualitative reduction in the
size and frequency of Oct-4-positive colonies concurrent with
quantitative reduction in metabolic activity compared with soluble
LIF supplementation (P< 0.01). By contrast treatmentwith PLGA and
NLG-LIF supported pluripotent marker (Oct-4)-positive colony
growth and metabolic activity, which was equivalent to soluble LIF
(shown for NLG). To evaluate whether treatment with nanoparticles
altered attachment to and coverage of the gelatin substrate provided,
cultures were evaluated using Electric Cell-substrate Impedance
Sensing (ECIS) [26,27]. By this method impedance of a non-invasive
Fig. 1. Nanoparticle characteristics. (a) For both PLGA and NLG-LIF is encapsulated in a core, which is surrounded by a phospholipid bilayer shell for the latter. Surface anchored
antibodies permit nanoparticle targeting. (b) Schematic of targeted activation of LIF receptor (LIF-R, green) on mESCs. Antibodies to SSEA-1 (black) on nanoparticles recognise SSEA-
1 (blue). LIF released (red) during nanoparticle degradation activates LIF-R. (c) SEM of PLGA nanoparticles. (d) Cumulative controlled release of LIF from PLGA. Mean  SD (n ¼ 3).
(For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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electrical current applied to cells grown on a substrate coated
microelectrode serves as a measure of cell coverage and integrity.
ECIS revealed no signiﬁcant differences (P > 0.05) between targeted
LIF-nanoparticle treated cultures and the soluble LIF positive control
after 3 days of growth. In contrast, cell impedance was signiﬁcantly
lower in cells treated with targeted empty nanoparticles and no
soluble LIF-negative controls (P < 0.01) (Fig. 4 a).
To conﬁrm the bioactivity of nanoparticle mediated delivery of
LIF we evaluated the phosphorylation of STAT-3 by Western blot-
ting. Cells stimulated with soluble LIF-supplemented medium
resulted in a pronounced 300-fold increase in STAT-3 phosphory-
lation within 10 min, as previously reported [28]. Treatment with
either targeted nanoparticle formulation was comparable to
negative controls. However, after 24 h, STAT-3 phosphorylation in
Fig. 2. Optimisation of afﬁnity targeted LIF delivery. (a) Exposure of mESCs on MEF feeders or MEF alone to rhodamine-labelled nanoparticles (10 mg/ml). Cells were incubated with
rhodamine-NLG or PLGAwithout (untargeted) or with (targeted) coating of anti-SSEA-1 antibody for afﬁnity targeting to mESCs. A red channel signal resulting from endocytosis of
nanoparticles is only observed in SSEA-1þ (green) colonies after treatment with targeted nanoparticles. (b) LIF provision by SSEA-1 targeted nanoparticles pre- and post-plating of
mESCs reveals treatment and formulation dependent support of total and ALPþ colony outgrowth (left and right, respectively). Mean values  SD (n ¼ 5) normalised to soluble LIF
(25 ng/ml). *P  0.05, **P  0.01. (c) Optimised feeder-free culture regime for mESCs cultured in basic medium with afﬁnity targeted nanoparticle mediated delivery of LIF. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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NLG-LIF treated cells was at least two-fold higher than in the
absence of LIF whereas PLGA-LIF and LIF-supplemented medium
before replenishment were comparable to the absence of LIF
(Fig. 4b). Consistent with these experiments, the growth kinetics of
the NLG-LIF over the ﬁrst 6 days of culture more closely mimicked
that observed for soluble LIF, whereas growth of PLGA supplied LIF
appeared to lag. By 7 days however, both nanoparticle formulations
supported more cumulative growth than in the absence of LIF
(Fig. 4c).
3.3. Long-term nanoparticles-mediated delivery of self-renewal
factors to stem cells supports pluripotency
Despite the apparent superior properties of the NLG formulation
to support mESC clonal outgrowth, STAT-3 phosphorylation and
feeder-free growth over short-term culture, we evaluated both
formulations using the optimised treatment protocol (Fig. 2c) for
competence to provide longer-term support over successive
passaging. After 5 weeks of continuous culture, in the course of
which cells were passaged 5 times and treated with NLG-LIF or
PLGA-LIF overnight once after each passage, maintenance of an
undifferentiated cell phenotype was conﬁrmed by immunocyto-
chemistry for Oct-4, and Nanog, RT-PCR for these markers, PEM and
Sox-2, and ﬂow cytometry for SSEA-1. By contrast, mESCs cultured
in the absence of LIF over this period manifest qualitative changes
consistent with loss of an undifferentiated phenotype including
reduction in colony size and pluripotency marker gene expression
(Fig. 5 and Fig. 6, aec). For both formulations, karyology analysis of
cells also conﬁrmed a normal karyotype of 40 XY chromosomes in
all of 30 spreads for each LIF-treatment group. Following embryoid
body mediated differentiation in vitro, cells also retained compe-
tence to forming beating cardiomycyte-like cells (shown for NLG-
LIF, online Video 1). Finally, analysis of differentiation potential at
this stage by injection of PLGA- and NLG-LIF treated mESCs under
the kidney capsule of the same strain of mice (129/Ola) conﬁrmed
their potential to generate teratomas composed of derivatives of all
three germinal lineages (Figs. 5 and 6, d).
Supplementary video related to this article can be found online
at doi:10.1016/j.biomaterials.2012.06.011.
4. Discussion
Our study reports an alternative approach to stem cell culture
focused on the use of biodegradable nanoparticles for afﬁnity tar-
geted paracrine stimulation. This approach offers several advan-
tages to conventional solubilisation of bioactive factors in media.
First, a high density of agent can often be encapsulated, dispersed
or dissolved within nanoparticles which, depending on the prep-
aration process, can be engineered to yield different properties and
release characteristics for the entrapped agent [29e33]. Second,
because of the versatility of chemistries and preparation methods
in these systems, surface functionalities can be incorporated into
the nanoparticle, facilitating additional attractive properties such
as attachment of target ligands for interaction with speciﬁc cells or
tissues. Such targeted delivery protects the agent from the
surroundingmedium, focuses the dose and delivers it in a paracrine
fashion in the case of extracellular targeting, or enhances the
intracellular dose upon endocytosis in internalizing cells [17,34].
Fig. 3. Effect of LIF nanoparticles on mESC viability. (a) NLG-LIF (10 mg/ml) support of expression of Oct-4 after 5 days of culture in a manner similar to daily supplementation of
basal medium with soluble LIF (25 ng/ml). Negative controls (no LIF) or LIF-free NLG (empty NP) are also shown. (b) WST-1 test indicating relative levels of metabolic activity for
mESCs treated with soluble LIF (25 ng/ml), NLG-LIF (10 mg/ml), no LIF and LIF-free NLG (empty NP). Signal (optical density: O.D.) normalised to positive control; error bars, SD
(n ¼ 3), **P  0.01. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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One of the most striking ramiﬁcations arising from the use of
afﬁnity targeted nanoparticles for the sustained release of bioactive
factors to achieve paracrine stimulation is the opportunity it
provides to reduce the quantity of bioactive factors consumed in
culture. In the case of our experiments, we calculated that
conventional culture of mESCs consumes 25 ng of LIF/ml/day,
amounting to 875 ng after 5 weeks of culture maintaining only
a single ml of cultured cells throughout. In contrast, using an
optimised concentration of 10 mg of NLG-LIF or of PLGA-LIF per
week, containing 0.01 ng of LIF, only 0.05 ng of LIF would be
consumed to achieve the same level of growth, a striking
1.74  104-fold reduction. To our knowledge this level of reduction
in the utilisation of a critical bioactive factor such as LIF in long-
term culture with successive passaging has not been achieved by
other methods of culture, such as for example by immobilisation on
biocarriers such as thin planar ﬁlms of maleic anhydride copolymer
or viral polyhedron protein surfaces [35,36]. Compared with
delivery by biodegradable encapsulant immobilised ligands are
exposed and thus more likely to degrade in culture media. Immo-
bilisation also precludes interaction with cells that are not in direct
contact. This would be a natural consequence of successive division
of cells growing as a domed colony as formESC. This would result in
differentiation and preclude long-term support of self-renewal,
although short-term culture is still tenable [35,36]. As bioactive
factors such as growth factors and cytokines are probably one of the
most expensive components of cell culture media the means to
control their delivery, bioactivity and usage would be of signiﬁcant
beneﬁt to translational industrial and clinical applications requiring
extensive culture of stem cells or derivatives, especially where
there is a reliance on complex cocktails of factors.
Our experience suggests that in complex culture systems, for
example in feeder-dependent systems, applying afﬁnity targeted
stimulation may require optimisation of treatment dosage. Theo-
retically, the temporal and spatial control this culture system offers
for the provision of bioactive factors could also be applied in other
contexts such as the positive or negative selection of cell subpop-
ulations in a heterogeneous culture environment, the expansion of
rare cells from primary tissue isolates and directed differentiation.
It is likely that placing an emphasis on targeted paracrine stimu-
lation could also alter the apparent requirement for bioactive
factors established by conventional culture systems. This could
generate an intellectual property pertaining to any given process.
To establish the generality of this paracrine delivery approach
we attempted to evaluate two types of nanoparticle formulations as
biodegradable vectors so as demonstrate that the beneﬁts of
paracrine stimulation was not necessarily a materials based
phenomenon. For this, we used well-established polyesters,
exempliﬁed by PLGA, which are commonly used as biodegradable
vectors and are known for their safety of use in humans. Their
degradation rate and the corresponding entrapped agent release
rate vary from days (PGA) to months (PLA) and are easily manip-
ulated by varying the ratio of PLA to PGA. PLGA nanoparticles can
also be formulated in a variety of ways that improve targeting to
speciﬁc cells [17,25]. The second class of carriers that are commonly
used in drug delivery applications are lipid-based. They are exem-
pliﬁed by liposomes or variants thereof such as the lipogel (lipo-
somewith a polymeric interior) used in this study, which are easily
modiﬁed for encapsulation of small hydrophilic or hydrophobic
molecules, and even nucleic acids and proteins [37,38]. The safety
proﬁles of both platforms comply in principle with regulatory
Fig. 4. Evaluation of mESC attachment and LIF-nanoparticle mediated signalling and growth kinetics. (a) ECIS assay of mESCs cultured in medium supplemented with soluble LIF, or
treated with PLGA- or NLG-LIF, as compared against no soluble LIF (no LIF) or LIF-free nanoparticles (empty NP). High resistance indicates good cell growth and hence electrode
coverage. **P  0.01. (b) STAT-3 phosphorylation. Upper panel: Western blotting of phosphorylated STAT-3 in mESCs 10 min and 24 h after treatment with medium lacking (no LIF)
or containing soluble LIF, or with empty (empty NP) or PLGA- or NLG-LIF. Middle panel shows levels of Oct-4 for comparison. Lower panel: Quantiﬁcation of STAT-3 phosphorylation
data normalised to no LIF at 10 min or 24 h post-treatment. (c) Supplementation of medium with NLG- or PLGA-LIF, or soluble LIF promotes cell growth over unsupplemented
medium (no LIF) for a period of 7 days. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 5. NLG-mediated provision of LIF over 5 weeks’ culture. (a) Nuclear DNA (DAPI) and immunocytochemical staining for Oct-4 and Nanog of mESCs that have been treated with
soluble LIF, NLG-LIF or no LIF. Scale bar: 100 mm (b) RT-PCR. Oct-4, Nanog, PEM and Sox-2 expression in mESCs treated with NLG-LIF vs soluble or no LIF. b-actin used as reference
gene. (c) Flow cytometry indicates variable but high maintenance of SSEA-1 in mESCs treated with NLG-LIF, similar to mESCs conventionally maintained with soluble LIF. (d)
Teratomas generated from mESCs treated with NLG-LIF for 5 weeks’ culture prior to injection. Ectoderm: (A) keratinised epithelium and (B) immature neuroectoderm (yellow
asterisk) and differentiated neural tissue (black asterisk). Mesoderm: (C) cartilage and (D) adipose tissue. Endoderm: (E) pulmonary epithelium and (F) gut epithelium. Scale bar:
50 mm. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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requirements for safety in stem cell manufacturing for therapeutic
applications. Our results from short-term culture experiments
suggested that LIF bioactivity might have been better preserved by
the NLG formulation as compared with PLGA. This may be due to
the amount of glycolic acid and lactic acid by products of the
polymer released during degradation. Compared with the PLGA
system, the NLG system encapsulates LIF using 70% less polymer
[24] by weight. A second possibility for the discrepancy in short-
term function may be simply due to the nature of the nano-
particles themselves. PLGA are solid biodegradable nanoparticles
compared to the vesicular, ﬂuid bilayer surface of the NLG. As such,
the cellenanoparticle interface in the short-term may be affected
by the mechanics of this interaction. In long-term culture however,
both particle formulations sustained mESC pluripotency, and
demonstrated the feasibility of a paracrine stimulation focused
approach to stem cell culture.
5. Conclusions
Our study illustrates an alternative paradigm for stem cell
culture, featuring artiﬁcial temporal and spatially controlled para-
crine stimulationwith the potential to improve the efﬁcacy of stem
cell culture. This system is capable of signiﬁcantly reducing the
consumption of a single critical bioactive factor in the context of
adherent cell culture in conventional tissue culture plasticware. We
anticipate this approach is likely to be adaptable to other stem cell
culture objectives, models and culture systems. As such we believe
the nanoparticles-mediated delivery of growth factors in cell
culture should contribute signiﬁcantly to the scaleablemanufacture
of stem cells and the clinical delivery of new advanced cellular
therapies for regenerative medicine.
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